Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Heron Therapeuti (HRTX)

NASDAQ
Currency in USD
Disclaimer
1.840
+0.020(+1.10%)
Closed
After Hours
1.790-0.050(-2.717%)
HRTX Scorecard
Full Analysis
Stock has taken a big hit over the last week
Fair Value
Day's Range
1.4301.840
52 wk Range
0.5003.930
Prev. Close
1.82
Open
1.81
Day's Range
1.43-1.84
52 wk Range
0.5-3.93
Volume
2,472,909
Average Vol. (3m)
2,176,763
1-Year Change
143.19%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
HRTX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
6.750
Upside
+266.848%
Members' Sentiments
Bearish
Bullish
ProTips
Stock price movements are quite volatile
Show more

Heron Therapeuti Company Profile

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Compare HRTX to Peers and Sector

Metrics to compare
HRTX
Peers
Sector
Relationship
P/E Ratio
−5.8x−2.2x−0.6x
PEG Ratio
−0.08−0.040.00
Price / Book
−7.4x0.6x2.6x
Price / LTM Sales
2.0x8.1x3.2x
Upside (Analyst Target)
253.3%378.1%43.9%
Fair Value Upside
Unlock38.2%7.8%Unlock

People Also Watch

0.899
PGEN
+7.19%
13.57
OMI
+0.82%
11.620
ATXS
+10.67%
0.391
AEMD
+2.60%
26.85
COLD
+0.52%

FAQ

What Is the Heron Therapeuti (HRTX) Stock Price Today?

The Heron Therapeuti stock price today is 1.84

What Stock Exchange Does Heron Therapeuti Trade On?

Heron Therapeuti is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Heron Therapeuti?

The stock symbol for Heron Therapeuti is "HRTX."

What Is the Heron Therapeuti Market Cap?

As of today, Heron Therapeuti market cap is 279.07M.

What is Heron Therapeuti Earnings Per Share?

The Heron Therapeuti EPS is -0.312.

What Is the Next Heron Therapeuti Earnings Date?

Heron Therapeuti will release its next earnings report on Nov 12, 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.